期刊文献+

溴甲酚紫、溴甲酚绿光度法测定阿昔洛韦 被引量:2

Spectrophotometric Method for Determination of Aciclovir with Bromocresol Purple and Bromocresol Green
下载PDF
导出
摘要 在pH3.30的NH2CH2COOH-NaCl-HCl缓冲介质中,阿昔洛韦(Aciclovir,ACV)可与溴甲酚紫(BCP)、溴甲酚绿(BCG)反应,形成离子缔合物,溶液颜色发生明显变化,其最大褪色波长分别为428nm(BCP-ACV)、450nm(BCG-ACV),在此波长处,阿昔洛韦的浓度与溶液褪色程度呈良好线性关系,可用分光光度法测定。在BCP-ACV、BCG-ACV体系的最大褪色波长处,ACV的浓度分别在0~2.69×10^-5 mol/L、0~2.58×10^-5 mol/L范围内遵守比耳定律,表观摩尔吸光系数分别为2.53×10^4 L·mol^-1·cm^-1、1.79×10^4 L·mol^-1·cm^-1,检出限分别为5.10×10^-7 mol/L、7.13×10^-7 mol/L。方法用于药品、血浆及尿液中阿昔洛韦的测定,结果满意。 A sensitive spectrophotometric method is developed for determination of aciclovir. In pH 3.30 NH2CH2COOH-NaCl-HCl buffer medium, aciclovir (ACV) reacts with bromocresol purple (BCP) or bromocresol green (BCG) to form an ion-association complex, the colours of solutions change obviously, the maximum fading wavelengths are at 428 nm(BCP-ACV) and 450 nm(BCG-ACV), respectively, and the fading intensity is proportional to the concentration of aciclovir. For BCP-ACV and BCG-ACV systems, the Beer's law are obeyed in the concentration range of 0-2.69×10^-5 mol/L and 0-2.58×10^-5 mol/L, the apparent molar absorptivity are 2.53×10^4 L·mol^-1·cm^-1 and 1.79×10^4 L·mol^-1·cm^-1 , and the detection limits of ACV are 5.10×10^-7 mol/L and 7. 13×10^-7 mol/L, respectively. The method has high sensitivity and fairly good selectivity, and has been applied to the determination of aciclovir in medicine samples and human serum and human urine with satisfactory results.
出处 《分析科学学报》 CAS CSCD 2008年第3期319-322,共4页 Journal of Analytical Science
基金 第二批“重庆市高等学校优秀中青年骨干教师资助计划”[渝教人(2005)2号] 长江师范学院科研项目(07Jkg50)
关键词 分光光度法 溴甲酚紫 溴甲酚绿 阿昔洛韦 Spectrophotometry Bromocresol purple Bromocresol green Aciclovir
  • 相关文献

参考文献9

二级参考文献24

  • 1张驰,董善年.反相高效液相色谱法测定人血浆中阿昔洛韦浓度[J].药学学报,1993,28(8):629-632. 被引量:15
  • 2陈镇生,韩加怡.盐酸氯丙嗪注射液的HPLC测定[J].中国医药工业杂志,1996,27(7):315-317. 被引量:3
  • 3Zhou Yuanyao(周元瑶). China Pharmacist(中国药师), 1998, 1(1): 85-95
  • 4Mahrous M S, Abdel-Khalek M M, Daabees H G. Anal Letters, 1992, 25∶1491-1498
  • 5Daabees H G. Analytical Letters, 1998, 31(9): 1509-1522
  • 6Stacy D B, Catherine A W, Chung K C, Michael G B. J. Chromatogr. B: Biomed. Appl., 2002, 772(2): 327-334
  • 7Jankowski A, Jankowska A L, Lamparczyk H. J. Pharm. Biomed. Anal., 1998, 18:(1-2): 249-254
  • 8Shi Xiaojin(施孝金), Zhang Lili(张莉莉), Li Dong(李东), Zhang Jinghua(张静华), Wang Hongtu(王宏图). Chinese Journal of Pharmaceuticals(中国医药工业杂志), 2002, 33 (3 ): 128-131
  • 9Shen Winston W, Urosevich Zoran, Clayton David O. Reprod. Med. [J],1999,44(6):535.
  • 10Garvey David S, Saenzde Teigada Inigo. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions, and use in treating sexual dysfunctions. U. S. USS. 958. 926(CI. 514-523;C07D241/04),28 Sep 1999, US Appl. 740764,INov 1996; 49pp.

共引文献35

同被引文献21

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部